SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.

Published online

Journal Article

Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft enzyme that regulates plasma membrane (PM) fluidity. Here we report that SMPDL3b excess, as observed in podocytes in diabetic kidney disease (DKD), impairs insulin receptor isoform B-dependent pro-survival insulin signaling by interfering with insulin receptor isoforms binding to caveolin-1 in the PM. SMPDL3b excess affects the production of active sphingolipids resulting in decreased ceramide-1-phosphate (C1P) content as observed in human podocytes in vitro and in kidney cortexes of diabetic db/db mice in vivo. Podocyte-specific Smpdl3b deficiency in db/db mice is sufficient to restore kidney cortex C1P content and to protect from DKD. Exogenous administration of C1P restores IR signaling in vitro and prevents established DKD progression in vivo. Taken together, we identify SMPDL3b as a modulator of insulin signaling and demonstrate that supplementation with exogenous C1P may represent a lipid therapeutic strategy to treat diabetic complications such as DKD.

Full Text

Duke Authors

Cited Authors

  • Mitrofanova, A; Mallela, SK; Ducasa, GM; Yoo, TH; Rosenfeld-Gur, E; Zelnik, ID; Molina, J; Varona Santos, J; Ge, M; Sloan, A; Kim, JJ; Pedigo, C; Bryn, J; Volosenco, I; Faul, C; Zeidan, YH; Garcia Hernandez, C; Mendez, AJ; Leibiger, I; Burke, GW; Futerman, AH; Barisoni, L; Ishimoto, Y; Inagi, R; Merscher, S; Fornoni, A

Published Date

  • June 19, 2019

Published In

Volume / Issue

  • 10 / 1

Start / End Page

  • 2692 -

PubMed ID

  • 31217420

Pubmed Central ID

  • 31217420

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/s41467-019-10584-4

Language

  • eng

Conference Location

  • England